Literature DB >> 12578223

In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories.

J D D'Amore1, S T Kajdasz, M E McLellan, B J Bacskai, E A Stern, B T Hyman.   

Abstract

Postmortem analyses of senile plaques reveal numerous dystrophic processes in their vicinity. We used in vivo multiphoton microscopy of a transgenic model of Alzheimer disease (AD) to simultaneously image senile plaques and nearby neuronal processes. Plaques were labeled by immunofluorescent staining or thioflavine-S and neuronal processes were labeled with a fluorescent dextran conjugate. Imaging of 3-dimensional volumes in the vicinity of plaques revealed subtle changes in neurite geometry in or near diffuse plaques. By contrast, disruptions in neurite morphology, including dystrophic neurites immediately surrounding plaques as well as major alterations in neurite trajectories, were seen in association with thioflavine-S-positive plaques. Nearly half of all labeled processes that came within 50 microm of a thioflavine-S-positive plaque were altered, suggesting a fairly large "halo" of neuropil alterations that extend beyond the discrete border of a thioflavine-S plaque. These results support the hypothesis that compact thioflavine-S-positive plaques disrupt the neuropil in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578223     DOI: 10.1093/jnen/62.2.137

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  52 in total

1.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease.

Authors:  B DaRocha-Souto; M Coma; B G Pérez-Nievas; T C Scotton; M Siao; P Sánchez-Ferrer; T Hashimoto; Z Fan; E Hudry; I Barroeta; L Serenó; M Rodríguez; M B Sánchez; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

2.  Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Aβ plaques in Alzheimer's disease.

Authors:  Kai Liu; Tai L Guo; Jeremy Chojnacki; Hyoung-Gon Lee; Xinglong Wang; Sandra L Siedlak; Wei Rao; Xiongwei Zhu; Shijun Zhang
Journal:  ACS Chem Neurosci       Date:  2011-12-11       Impact factor: 4.418

3.  Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy.

Authors:  Allan Wang; Pritam Das; Robert C Switzer; Todd E Golde; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

4.  On chip two-photon metabolic imaging for drug toxicity testing.

Authors:  Fang Yu; Shuangmu Zhuo; Yinghua Qu; Deepak Choudhury; Zhiping Wang; Ciprian Iliescu; Hanry Yu
Journal:  Biomicrofluidics       Date:  2017-05-11       Impact factor: 2.800

5.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors:  Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 6.  Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B.

Authors:  Keith A Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

7.  Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.

Authors:  Tara L Spires; Melanie Meyer-Luehmann; Edward A Stern; Pamela J McLean; Jesse Skoch; Paul T Nguyen; Brian J Bacskai; Bradley T Hyman
Journal:  J Neurosci       Date:  2005-08-03       Impact factor: 6.167

8.  Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease.

Authors:  Jennifer B Paulson; Martin Ramsden; Colleen Forster; Mathew A Sherman; Eileen McGowan; Karen H Ashe
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

9.  Long-Term Mangiferin Extract Treatment Improves Central Pathology and Cognitive Deficits in APP/PS1 Mice.

Authors:  Carmen Infante-Garcia; Juan Jose Ramos-Rodriguez; Irene Delgado-Olmos; Carlos Gamero-Carrasco; Maria Teresa Fernandez-Ponce; Lourdes Casas; Casimiro Mantell; Monica Garcia-Alloza
Journal:  Mol Neurobiol       Date:  2016-07-21       Impact factor: 5.590

10.  Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

Authors:  Monica Garcia-Alloza; Meenakshi Subramanian; Diana Thyssen; Laura A Borrelli; Abdul Fauq; Pritam Das; Todd E Golde; Bradley T Hyman; Brian J Bacskai
Journal:  Mol Neurodegener       Date:  2009-05-06       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.